Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Drug Res (Stuttg) ; 74(2): 47-52, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38232750

ABSTRACT

Heart failure is a health problem worldwide. There are some drugs for it, including digoxin, spironolactone, captopril, and valsartan, but some of these drugs can produce secondary effects, such as arrhythmia, cough, hyperkalemia, hyponatremia and hypotension. The aim of this research was to evaluate the biological activity of coumarin (2H-chromen-2-one) and its derivatives (3BrAcet-C, 3-4Br-Ph-C, 4-CN-7D-C, 4-Me-7-Ph-C and 6Br-3-D-C) against ischemia/reperfusion injury as a therapeutic alternative for heart failure. In addition, the biological activity of the coumarin derivative 4-Me-7-Ph-C on left ventricular pressure (LVP) was determined in the absence or presence of ouabain and nifedipine at a dose of 1 nM using an isolated rat heart model. The results showed that i) the coumarin derivative 4-Me-7-Ph-C significantly decreased the infarct area (p+=+0.05) compared with 3BrAcet-C, 3-4Br-Ph-C, 4-CN-7D-C, and 6Br-3-D-C; and ii) 4-Me-7-Ph-C increased LVP in a dose-dependent manner, which effect was inhibited by nifedipine. These data suggest that coumarin 4-Me-7-Ph-C may act as a type-L calcium channel activator, so it could be a good agent to treat heart failure.


Subject(s)
Heart Failure , Myocardial Reperfusion Injury , Rats , Animals , Nifedipine/pharmacology , Nifedipine/therapeutic use , Myocardial Reperfusion Injury/drug therapy , Heart Failure/drug therapy , Coumarins/pharmacology , Coumarins/therapeutic use , Ischemia , Heart
2.
Drug Res (Stuttg) ; 73(6): 355-364, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37172939

ABSTRACT

BACKGROUND: Some studies indicate that the angiogenesis process is related to vascular endothelial growth factor, which can interact with endothelial cell surface receptors (VEGF-R1, VEGF-R2, and VEGF-R3); this biochemical process and other factors result in the promotion and growth of new blood vessels under normal conditions. However, some studies indicate that this phenomenon could also occur in cancer cells. It is important to mention that some amino derivatives have been prepared as VEGF-R1 inhibitors; however, their interaction with VEGF-R1 is not clear, perhaps due to different experimental approaches or differences in their chemical structure. OBJECTIVE: The aim of this study was to evaluate the theoretical interaction of several amino-nitrile derivatives (Compounds 1 to 38) with VEGF-R1. METHODS: The theoretical interaction of amino-nitrile derivatives with VEGF-R1 was carried out using the 3hng protein as the theoretical model. In addition, cabozantinib, pazopanib, regorafenib, and sorafenib were used as controls in the DockingServer program. RESULTS: The results showed different amino acid residues involved in the interaction of amino-nitrile derivatives with the 3hng protein surface compared with the controls. In addition, the inhibition constant (Ki) was lower for Compounds 10 and 34 than for cabozantinib. Other results show that Ki for Compounds 9, 10, 14, 27-29 and 34-36 was lower in comparison with pazopanib, regorafenib, and sorafenib. CONCLUSIONS: All theoretical data suggest that amino-nitrile derivatives could produce changes in the growth of some cancer cell lines through VEGFR-1 inhibition. Therefore, these amino-nitrile derivatives could be a therapeutic alternative to treat some types of cancer.


Subject(s)
Neoplasms , Vascular Endothelial Growth Factor Receptor-1 , Humans , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vascular Endothelial Growth Factor A/metabolism , Sorafenib , Neoplasms/drug therapy , Models, Theoretical
3.
Drug Res (Stuttg) ; 73(5): 263-270, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36858071

ABSTRACT

BACKGROUND: Some studies show that some Dibenzo derivatives can produce changes in the cardiovascular system; however, its molecular mechanism is not very clear. OBJECTIVE: The objective of this investigation was to evaluate the inotropic activity of ten Dibenzo derivatives (compounds 1 to 10) on either perfusion pressure or left ventricular pressure. METHODS: Biological activity produced by the Dibenzo derivatives on either perfusion pressure or coronary resistance was evaluated using an isolated rat heart. In addition, the molecular mechanism of biological activity produced by compound 4 (Dibenzo[b,e]thiophene-11(6H)-one) on left ventricular pressure was determined using both Bay-k8644 and nifedipine as pharmacological tools in an isolated rat heart model. RESULTS: The results showed that Dibenzo[b,e]thiophene-11(6H)-one increases perfusion pressure and coronary resistance at a dose of 0.001 nM. Besides, other data display that Dibenzo[b,e]thiophene-11(6H)-one increases left ventricular pressure in a dose-dependent manner (0.001 to 100 nM) and this effect was similar to biological activity produced by Bay-k8644 drug on left ventricular pressure. However, the effect exerted by Dibenzo[b,e]thiophene-11(6H)-one was inhibited in the presence of nifedipine at a dose of 1 nM. CONCLUSIONS: All these data suggest that Dibenzo[b,e]thiophene-11(6H)-one increase left ventricular pressure through calcium channel activation. In this way, Dibenzo[b,e]thiophene-11(6H)-one could be a good candidate as positive inotropic agent to heart failure.


Subject(s)
Heart , Nifedipine , Rats , Animals , Nifedipine/pharmacology , Ventricular Pressure , 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester/pharmacology
4.
J Chem Biol ; 10(2): 69-84, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28405241

ABSTRACT

The aims of this study were to evaluate the positive inotropic effect of a new macrocyclic derivative (compound 11) and characterize the molecular mechanism involved in its biological activity. The first step was achieved by synthesis of a macrocyclic derivative involving a series of reactions for the preparation of several steroid derivatives such as (a) steroid-pyrimidinone (3 and 4), (b) steroid-amino (5), (c) steroid-imino (6), (d) ester-steroid (7 and 8), and (e) amido-steroid (9 and 10). Finally, 11 was prepared by removing the tert-butyldimethylsilane fragment of 10. The biological activity of compounds on perfusion pressure and vascular resistance was evaluated on isolated rat heart using the Langendorff model. The inotropic activity of 11 was evaluated in presence of prazosin, metoprolol, indomethacin, nifedipine, and flutamide to characterize its molecular mechanism. Theoretical experiments were carried out with a Docking model, to assess potential interactions of androgen receptor with 11. The results showed that only this macrocyclic derivative exerts changes on perfusion pressure and vascular resistance translated as the positive inotropic effect, and this effect was blocked with flutamide; these data indicate that the positive inotropic activity induced by this macrocyclic derivative was via androgen receptor activation. The theoretical results indicated that the interaction of the macrocyclic derivative with the androgen receptor involves several amino acid residues such as Leu704, Asn705, Met780, Cys784, Met749, Leu762, Phe764, Ser778, and Met787. In conclusion, all these data suggest that the positive inotropic activity of the macrocyclic derivative may depend on its chemical structure.

5.
Cardiovasc Hematol Agents Med Chem ; 14(2): 125-133, 2017.
Article in English | MEDLINE | ID: mdl-27889993

ABSTRACT

BACKGROUND: There are data indicating that several azonine-derivatives may exert effects on some biological systems; however, there is very low information on the biological activity induced by these compounds on left ventricular pressure. OBJECTIVE: The aim of this study was to synthesize and evaluate the biological activity of new triazoninederivative on left ventricular pressure. MATERIAL AND METHODS: The first stage involved: 1) preparation of two azepine-benzamide derivatives (Z or E) by reaction of the nitrobenzoyl azide with adrenosterone; and 2) reaction of (Z)-azepine-benzamide derivative with ethylenediamine to form the triazonine derivative. The structure of compounds was confirmed by spectroscopy and spectrometry data. The second stage involved the biologic activity on left ventricular pressure was evaluated in a model of rat heart isolated. In addition, some physicochemical parameters were evaluated to characterize the possible molecules involved in its effect. RESULTS: The results showed that only the triazonine increased left ventricular pressure via androgen receptor. CONCLUSIONS: In conclusion, this phenomenon is conditioned by the functional groups involved in the chemical structure of triazonine derivative and their interaction with residues of amino acids involved on the androgen receptor surface.


Subject(s)
Azepines/chemistry , Azepines/pharmacology , Heterocyclic Compounds, 4 or More Rings/chemistry , Heterocyclic Compounds, 4 or More Rings/pharmacology , Receptors, Androgen/metabolism , Ventricular Function, Left/drug effects , Ventricular Pressure/drug effects , Animals , Azepines/chemical synthesis , Benzamides/chemical synthesis , Benzamides/chemistry , Heterocyclic Compounds, 4 or More Rings/chemical synthesis , Humans , Male , Molecular Docking Simulation , Rats, Wistar
6.
J Pediatr Endocrinol Metab ; 29(10): 1143-1150, 2016 Oct 01.
Article in English | MEDLINE | ID: mdl-27658130

ABSTRACT

BACKGROUND: This study sought to investigate the effects of omega (ω)-3 polyunsaturated fatty acid (PUFA) supplementation on the lipid profiles and glucose (GLU) levels of overweight (OW) schoolchildren with metabolic syndrome (MS). METHODS: Thirty-nine OW schoolchildren with MS, including 19 girls and 20 boys, received 1-month of dietary supplementation with gel capsules containing ω-3 fatty acids. Fasting lipid profiles and GLU levels were measured before and after supplementation. RESULTS: Both sexes of OW schoolchildren with MS who received daily supplementation with 2.4 g of ω-3 fatty acids for 1 month displayed improved lipid profiles, reduced fasting GLU levels and reduced blood pressure (BP). CONCLUSIONS: These findings support the addition of omega-3 fatty acid supplementation to programs aiming to improve the metabolic status of OW children with MS, although additional research on the longer-term safety and efficacy of this treatment in this population is required.


Subject(s)
Blood Glucose/analysis , Blood Pressure/drug effects , Fatty Acids, Omega-3/administration & dosage , Lipids/blood , Metabolic Syndrome/drug therapy , Overweight/complications , Body Mass Index , Case-Control Studies , Child , Cross-Sectional Studies , Female , Humans , Male , Metabolic Syndrome/blood , Metabolic Syndrome/etiology , Time Factors
7.
Acta bioquím. clín. latinoam ; 48(2): 203-211, jun. 2014. ilus, graf
Article in Spanish | LILACS | ID: lil-734228

ABSTRACT

Existen pocos datos con respecto a los efectos de la brucina y sus derivados en el aparato cardiovascular; además, el mecanismo molecular y su sitio de acción celular no son claros. Para proporcionar información adicional acerca de este fenómeno, en este trabajo fue evaluado el efecto inducido por un derivado de la brucina sobre la presión de perfusión, la resistencia vascular y la presión ventricular izquierda en corazón aislado de rata a flujo constante (modelo de Langendorff). Los resultados mostraron que; 1) el derivado brucina (1×10-9 mM) incrementa la presión de perfusión y la resistencia vascular en comparación con la brucina (1×10-9 mM) y las condiciones de control; 2) los efectos del derivado de brucina en dosis de 1×10-9 a 1×10-4 mM sobre la presión intraventricular no fueron inhibidos por metoprolol, prazosina o nifedipino a dosis de 1×10-6 mM; y 3) la furosemida a dosis de 1×10-6 mM bloquea los efectos ejercidos por el derivado de brucina (1×10-9 a 1×10-4 mM) sobre la presión intraventricular. En conclusión, la actividad ejercida por el derivado de brucina sobre la presión ventricular izquierda, involucra inhibición de la bomba Na+/K+-ATPasa, lo que trae indirectamente cambios en los niveles de calcio intracelular y subsecuentemente un efecto inotrópico positivo.


Few data exist with respect to the effects of brucine and its derivatives at a cardiovascular level; furthermore, the molecular mechanism and its site of cellular action are still unclear. In order to provide additional information about this phenomenon, the effect induced by a brucine derivative on perfusion pressure, vascular resistance and left ventricular pressure was evaluated in anisolated rat heart at constant flow (Langendorff model). The results showed that: 1) The brucine derivative [1×10-9 mM] increased perfusion pressure and vascular resistance in comparison with the brucine [1×10-9 mM] and the control conditions; 2) the effects of brucine derivative [1×10-9 to 1×10-4 mM] on intraventricular pressure were not inhibited by metoprolol, prazosin or nifedipine at a 1×10-6 mM dose; 3) furosemide [1×10-6 mM] blocked the effects exerted by the brucine derivative [1×10-9 a 1×10-4 mM] on intraventricular pressure. In conclusion, the activity exerted by the brucine derivative on perfusion pressure, vascular resistance and left ventricular pressure, involves inhibition of Na+/K+-ATPase, consequently resulting in indirect changes in intracellular calcium levels and subsequently inducing a positive inotropic effect.


Existem poucos dados no que diz respeito aos efeitos da brucina e seus derivados no nível cardiovascular; além disso, o mecanismo molecular e seu local de ação celular não são claros. Para fornecer informações adicionais sobre este fenômeno, neste trabalho foi avaliado o efeito induzido por um derivado de brucina sobre a pressão de perfusão, a resistência vascular e a pressão ventricular esquerda em coração isolado de ratos em fluxo constante (modelo Langendorff). Os resultados mostraram que: 1) o derivado brucina (1×10-9 mM) aumenta a pressão de perfusão e a resistência vascular em comparação com a brucina (1×10-9 mM) e as condições de controle; 2) os efeitos do derivado de brucina em doses de 1×10-9 a 1×10-4 mM sobre a pressão intraventricular não foram inibidos por metoprolol, prazosina ou nifedipino em doses de 1×10-6 mM; e 3) a furosemida, em doses de 1×10-6 mM, bloqueia os efeitos exercidos pelo derivado de brucina (1×10-9 a 1×10-4 mM) sobre a pressão intraventricular. Em conclusão, a atividade exercida pelo derivado de brucina sobre a pressão ventricular esquerda, envolve a inibição da bomba de Na+/K+-ATPase, o que indiretamente traz alterações nos níveis de cálcio intracelular e, subsequentemente, um efeito inotrópico positivo.


Subject(s)
Animals , Mice , Cardiotonic Agents , Cardiotonic Agents/analysis , Heart Failure , Coronary Vessels , Heart , Nifedipine , Vascular Resistance
8.
Acta bioquím. clín. latinoam ; 48(2): 203-211, jun. 2014. ilus, graf
Article in Spanish | BINACIS | ID: bin-131578

ABSTRACT

Existen pocos datos con respecto a los efectos de la brucina y sus derivados en el aparato cardiovascular; además, el mecanismo molecular y su sitio de acción celular no son claros. Para proporcionar información adicional acerca de este fenómeno, en este trabajo fue evaluado el efecto inducido por un derivado de la brucina sobre la presión de perfusión, la resistencia vascular y la presión ventricular izquierda en corazón aislado de rata a flujo constante (modelo de Langendorff). Los resultados mostraron que; 1) el derivado brucina (1Î10-9 mM) incrementa la presión de perfusión y la resistencia vascular en comparación con la brucina (1Î10-9 mM) y las condiciones de control; 2) los efectos del derivado de brucina en dosis de 1Î10-9 a 1Î10-4 mM sobre la presión intraventricular no fueron inhibidos por metoprolol, prazosina o nifedipino a dosis de 1Î10-6 mM; y 3) la furosemida a dosis de 1Î10-6 mM bloquea los efectos ejercidos por el derivado de brucina (1Î10-9 a 1Î10-4 mM) sobre la presión intraventricular. En conclusión, la actividad ejercida por el derivado de brucina sobre la presión ventricular izquierda, involucra inhibición de la bomba Na+/K+-ATPasa, lo que trae indirectamente cambios en los niveles de calcio intracelular y subsecuentemente un efecto inotrópico positivo.(AU)


Few data exist with respect to the effects of brucine and its derivatives at a cardiovascular level; furthermore, the molecular mechanism and its site of cellular action are still unclear. In order to provide additional information about this phenomenon, the effect induced by a brucine derivative on perfusion pressure, vascular resistance and left ventricular pressure was evaluated in anisolated rat heart at constant flow (Langendorff model). The results showed that: 1) The brucine derivative [1Î10-9 mM] increased perfusion pressure and vascular resistance in comparison with the brucine [1Î10-9 mM] and the control conditions; 2) the effects of brucine derivative [1Î10-9 to 1Î10-4 mM] on intraventricular pressure were not inhibited by metoprolol, prazosin or nifedipine at a 1Î10-6 mM dose; 3) furosemide [1Î10-6 mM] blocked the effects exerted by the brucine derivative [1Î10-9 a 1Î10-4 mM] on intraventricular pressure. In conclusion, the activity exerted by the brucine derivative on perfusion pressure, vascular resistance and left ventricular pressure, involves inhibition of Na+/K+-ATPase, consequently resulting in indirect changes in intracellular calcium levels and subsequently inducing a positive inotropic effect.(AU)


Existem poucos dados no que diz respeito aos efeitos da brucina e seus derivados no nível cardiovascular; além disso, o mecanismo molecular e seu local de aþÒo celular nÒo sÒo claros. Para fornecer informaþ§es adicionais sobre este fen¶meno, neste trabalho foi avaliado o efeito induzido por um derivado de brucina sobre a pressÒo de perfusÒo, a resistÛncia vascular e a pressÒo ventricular esquerda em coraþÒo isolado de ratos em fluxo constante (modelo Langendorff). Os resultados mostraram que: 1) o derivado brucina (1Î10-9 mM) aumenta a pressÒo de perfusÒo e a resistÛncia vascular em comparaþÒo com a brucina (1Î10-9 mM) e as condiþ§es de controle; 2) os efeitos do derivado de brucina em doses de 1Î10-9 a 1Î10-4 mM sobre a pressÒo intraventricular nÒo foram inibidos por metoprolol, prazosina ou nifedipino em doses de 1Î10-6 mM; e 3) a furosemida, em doses de 1Î10-6 mM, bloqueia os efeitos exercidos pelo derivado de brucina (1Î10-9 a 1Î10-4 mM) sobre a pressÒo intraventricular. Em conclusÒo, a atividade exercida pelo derivado de brucina sobre a pressÒo ventricular esquerda, envolve a inibiþÒo da bomba de Na+/K+-ATPase, o que indiretamente traz alteraþ§es nos níveis de cálcio intracelular e, subsequentemente, um efeito inotrópico positivo.(AU)

9.
Article in English | MEDLINE | ID: mdl-22660221

ABSTRACT

AIM: The present study was designed to investigate the effects of progesterone-carbachol derivative on perfusion pressure and coronary resistance in rats. An additional aim was to identify the molecular mechanisms involved. METHODS: The Langendorff model was used to measure perfusion pressure and coronary resistance changes in isolated rat heart after progesterone-carbachol derivative alone and after the following compounds; mifepristone (progesterone receptor blocker), yohimbine (α2 adreno-receptor antagonist), ICI 118,551 (selective ß2 receptor blocker), atropine (non-selective muscarinic receptor antagonist), methoctramine (antagonist of M2 receptor) and L-NAME (inhibitor of nitric oxide synthase). RESULTS: The results show that progesterone-carbachol derivative [10(-9) mM] significantly decreased perfusion pressure (P=0.005) and coronary resistance (P=0.006) in isolated rat heart. Additionally, the effect of progesterone-carbachol on perfusion pressure [10(-9) to 10(-4) mM] was only blocked in the presence of methoctramine and L-NAME. CONCLUSIONS: These data suggest that progesterone derivative exert its effect on perfusion pressure via activation of the M2 muscarinic. In addition, this phenomenon involves stimulation of nitric oxide synthase (NOS).


Subject(s)
Blood Pressure/drug effects , Carbachol/analogs & derivatives , Coronary Vessels/drug effects , Progesterone/analogs & derivatives , Receptor, Muscarinic M2/drug effects , Vascular Resistance/drug effects , Animals , Carbachol/pharmacology , Coronary Vessels/physiology , Male , Progesterone/pharmacology , Rats
10.
Article in English | MEDLINE | ID: mdl-22660215

ABSTRACT

AIM: The present study was designed to investigate the activity of two glibenclamide derivatives on glucose concentration. An additional aim was to identify the biodistribution of glibenclamide derivatives in different organs in a diabetic animal model. METHODS: The effects of two glibenclamide derivatives on glucose concentration were evaluated in a diabetic animal model. In addition, glibenclamide derivatives were bound to Tc-99m using radioimmunoassay methods. To evaluate the pharmacokinetics of the glibenclamide derivatives over time (15, 30, 45 and 60 min) the Tc-99m-glibenclamide conjugates were used. RESULTS: The results showed that glibenclamide-pregnenolone had greater hypoglycemic activity than glibenclamide or glibenclamide-OH. The data also showed that the biodistribution of Tc-99m-glibenclamide-OH in all organs was less than that of the Tc-99m-glibenclamide-pregnenolone derivative. CONCLUSIONS: The glibenclamide-pregnenolone derivative had greater hypoglycemic effects and its biodistribution was wider than glibenclamide-OH. The data suggest that the steroid nucleus may be important to the hypoglycemic activity of the glibenclamide-pregnenolone derivative and this could be related to the degree of lipophilicity induced by the steroid nucleus in the chemical structure of glibenclamide-pregnenolone.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Experimental/blood , Glyburide/therapeutic use , Pregnenolone/therapeutic use , Alloxan , Animals , Drug Combinations , Female , Glyburide/analogs & derivatives , Glyburide/pharmacokinetics , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/pharmacokinetics , Metformin/therapeutic use , Pregnenolone/pharmacokinetics , Rats , Rats, Wistar , Tissue Distribution
11.
Biomedica ; 31(2): 232-41, 2011 Jun.
Article in Spanish | MEDLINE | ID: mdl-22159540

ABSTRACT

Inotropic activity induced by carbamazepine-alkyne derivative in an isolated heart model and perfused to constant flow Introduction. Few data exist with respect to the effects of carbamazepine and its derivatives at cardiovascular level; furthermore, the molecular mechanisms and cellular site of action are still unclear. Objective. The effects induced by carbamazepine-alquine derivative on perfusion pressure, vascular resistance and left ventricular pressure were evaluated. Materials and methods. The effects of carbamazepine and carbamazepine-alquine on the perfusion pressure, vascular resistance and left ventricular pressure were examined in isolated rat hearts (Langendorff model). Results. Four results were obtained: (1) The carbamazepine-alquine derivative 10-9 mM increased the perfusion pressure and vascular resistance in comparison with the carbamazepine 10-9 mM; (2) the effect of carbamazepine-alquine derivative 10-9-10-4 mM on left ventricular pressure not was inhibited by metoprolol or prazosin at a dose of 10-6 mM; (3) nifedipine 10-6 mM blocked the effects exerted by the carbamazepine-alquine derivative 10-9-10--4 mM on left ventricular pressure, and (4) the carbamazepine-alquine derivative at dose of 10-9 mM increased the concentration of intracellular calcium over a time period of 3-18 min; nevertheless, in presence of nifedipine 10-6 mM this effect was inhibited significantly (p=0.005). Conclusions. The activity exerted by carbamazepine-alquine derivative on perfusion pressure, vascular resistance and left ventricular pressure involved activation of calcium channel type-L, brought indirectly changes in the intracellular calcium levels and subsequently induced a positive inotropic effect.


Subject(s)
Alkynes/pharmacology , Carbamazepine/chemistry , Carbamazepine/pharmacology , Heart/drug effects , Heart/physiology , Myocardial Contraction/drug effects , Alkynes/chemistry , Animals , Calcium/metabolism , Calcium Channels, L-Type/metabolism , Molecular Structure , Perfusion , Rats , Rats, Wistar , Stimulation, Chemical , Vascular Resistance/drug effects , Ventricular Pressure/drug effects
12.
Biomédica (Bogotá) ; 31(2): 232-241, jun. 2011. graf, tab, ilus
Article in Spanish | LILACS | ID: lil-617521

ABSTRACT

Introducción. Existen pocos datos con respecto a los efectos de la carbamacepina y sus derivados en el aparato cardiovascular; además, el mecanismo molecular y su sitio de acción celular no son claros. Objetivo. Evaluar los efectos inducidos por el derivado carbamacepina-alquino sobre la presión de perfusión, la resistencia vascular y la presión ventricular izquierda. Materiales y métodos. Los efectos de la carbamacepina y del derivado carbamacepina-alquino sobre la presión de perfusión, la resistencia vascular y la presión ventricular izquierda fueron evaluados en un modelo de corazón aislado de rata (Langendorff). Resultados. Se encontró que: 1) el derivado carbamacepina-alquino (1x10 -9 mM) incrementa la presión de perfusión y la resistencia vascular en comparación con la carbamacepina (1×10 -9 mM); 2) los efectos del derivado carbamacepina-alquino (1×10 -9 -1×10 -4 M) sobre la presión intraventricular no fueron inhibidos por metoprolol o prazosina (1×10 -6 mM); 3); el nifedipino (1×10 -6 mM) bloquea los efectos ejercidos por el derivado carbamacepina-alquino (1×10 -9 -1×10 -4 M) sobre la presión intraventricular, y 4) el efecto del derivado de carbamacepina (1×10 -9 mM) incrementa la concentración de calcio intracelular a través del tiempo (3 a 18 minutos); sin embargo, en presencia de nifedipino (1×10-6 mM), este efecto disminuye significativamente (p=0,005). Conclusiones. La actividad ejercida por el derivado carbamacepina-alquino sobre la presión de perfusión, la resistencia vascular y la presión intraventricular, involucra la activación del canal de calcio de tipo L, lo que trae como consecuencia indirecta cambios en los niveles de calcio intracelular y, subsecuentemente, induce un efecto inotrópico positivo.


Subject(s)
Carbamazepine , Heart , Nifedipine , Vascular Resistance , Ventricular Pressure , Calcium Channel Agonists
13.
Acta bioquím. clín. latinoam ; 44(1): 37-45, ene.-mar. 2010. graf
Article in Spanish | LILACS | ID: lil-633107

ABSTRACT

Estudios clínicos y epidemiológicos sugieren que el danazol ha sido considerado como un factor de riesgo para desarrollar hipertensión. Para proporcionar información adicional acerca de este fenómeno, en este trabajo fue caracterizado el efecto inducido por el danazol y el hemisuccinato de danazol sobre la presión de perfusión y la resistencia vascular en corazón aislado de rata a flujo constante (modelo de Langendorff). Los resultados, mostraron que; 1) el hemisuccinato de danazol [10-9 M] incrementa la presión de perfusión en comparación con el danazol [10-9 M]; 2) los efectos del derivado de danazol [10-9 M - 10-4 M] sobre la presión de perfusión fueron inhibidos por flutamida [10-6 M]; 3) la nifedipina [10-6 M], bloqueó los efectos ejercidos por el hemisuccinato de danazol [10-9 M -10-4 M] sobre la presión de perfusión y 4) el efecto del derivado de danazol [10-9 M - 10-4 M] sobre la presión de perfusión en presencia del montelukast [10-6 M] fue inhibido significativamente (p=0,008). En conclusión, los efectos inducidos por el danazol y hemisuccinato de danazol sobre la presión de perfusión y la resistencia vascular podrían depender de su estructura química. Este fenómeno podría involucrar la interacción del receptor de andrógenos e indirectamente la activación de la síntesis de leucotrienos D4 (LTD4) y consecuentemente inducir variaciones en la presión de perfusión.


Epidemiological and clinical studies suggest that danazol has been considered a risk factor for hypertension development. In order to provide additional information about this phenomenon, the effect induced by both danazol and hemisuccinate of danazol on perfusion pressure and vascular resistance was characterized in isolated rat heart at constant flow (Langendorff model) and it was evaluated in this work.The results showed that; 1) hemisuccinate of danazol [10-9 M] increases perfusion pressure and vascular resistance in comparison with danazol [10-9 M]; 2) the effects of danazol-derivative [10-9 M - 10-4 M] on perfusion pressure were inhibited by flutamide [10-6 M]; 3) nifedipine [10-6 M] blockaded the effects exerted by hemisuccinate of danazol [10-9 M -10-4 M] on perfusion pressure; and 4) the effect of danazol-derivative [10-9 M - 10-4 M] on perfusion pressure in presence of montelukast [10-6 M] was significantly inhibited (p=0.008). In conclusion, the effects induced by both danazol and hemisuccinate of danazol on perfusion pressure and vascular resistance could depend on their chemical structure. This phenomenon could involve the interaction of androgene steroid-receptor and indirect activation of leukotriene D4 (LTD4) synthesis and consequently, induce variations in the perfusion pressure.


Subject(s)
Animals , Rats , Methylprednisolone Hemisuccinate/pharmacology , Danazol/adverse effects , Danazol/pharmacology , Vascular Resistance/drug effects , Coronary Vessels/drug effects , Danazol/analysis , Isolated Heart Preparation
14.
Rev. bras. farmacogn ; 19(4): 898-907, out.-dez. 2009. tab, ilus
Article in Spanish | LILACS | ID: lil-542706

ABSTRACT

Varias plantas con propiedades hipoglucemicas se han utilizado en medicina popular y sistemas curativos tradicionales en todo el mundo. El propósito de este trabajo fue evaluar los efectos inducidos por Ruta graveolens L., Rutaceae, Cnidoscolus chayamansa McVaugh, Euphorbiaceae, y Citrus aurantium L., Rutaceae, en un modelo de rata diabética, a la que se le cuantificaron los niveles de glucosa cada 24 horas por un mes después de la administración gástrica del extracto de las plantas. Además, el colesterol y los triglicéridos fueron evaluados usando técnicas enzimáticas. Los resultados mostraron que la administración de Cnidoscolus chayamansa a dosis de 0.5 a 1.5 g/kg induce un aumento hipoglucemico (< 200 mg/dL). Otros datos indican que Cnidoscolus chayamansa ejerce variaciones en los niveles de triacilglicéridos (80-90 mg/dL) y colesterol (88-96 mg/dL). Sin embargo, la administración de Citrus aurantium en las mismas dosis no fue suficiente para disminuir los niveles de glucosa (> 200 mg/dL). Otros resultados, mostraron que Citrus aurantium ejerce cambios en la concentración de triacilglicéridos (158-172 mg/dL) y colesterol (120-128 mg/dL). Finalmente, la administración de Ruta graveolens a dosis de 0.5 g/kg induce un efecto hipoglucemico (< 200 mg/dL). Además, Ruta graveolens a dosis de 0.5 a 1.5 g/kg induce variaciones en los niveles de triacilglicéridos (110-120 mg/dL) y colesterol (116-124 mg/dL). En conclusión la administración de Cnidoscolus chayamansa ejerce efectos hipoglucemicos en una manera dosis dependiente en comparación con Ruta graveolens y Citrus aurantium. Además, las plantas evaluadas inducen cambios en los niveles de lípidos dependiente de la dosis.


Diversas plantas com propriedades hipoglicêmicas foram usadas na medicina popular e em sistemas tradicionais de curas em torno do mundo. A finalidade deste trabalho foi avaliar os efeitos induzidos por Ruta graveolens L, Rutaceae, Cnidoscolus chayamansa McVaugh, Euphorbiaceae, e Citrus aurantium L., Rutaceae, em modelo do rato diabético onde níveis da glucose foram determinados a cada 24 h em um mês antes da administração gástrica do extrato das plantas. Colesterol e triacilglicerídeos foram avaliados usando técnicas enzimáticas. Os resultados mostraram que a administração de Cnidoscolus chayamansa a dose de 0,5 a 1,5 g/kg induz um aumento hipoglicêmico (< 200 mg/dL). Outros dados indicam que Cnidoscolus chayamansa exerce variações nos níveis de triacilglicerídeos (80-90 mg/dL) e colesterol (88-96 mg/dL). A administração de Citrus aurantium nas mesmas doses não foi suficiente para diminuir os níveis de glucose (> 200 mg/dL). Outros resultados, mostraram que Citrus aurantium exerce mudanças na concentração de triacilglicerídeos (158-172 mg/dL) e colesterol (120-128 mg/dL). Finalmente, a administração de Ruta graveolens na dose de 0.5 g/kg induziu um efeito hipoglicêmico (< 200 mg/dL). Ruta graveolens, na dose de 0.5 a 1.5 g/kg, induziu variações nos níveis de triacilglicerídeos (110-120 mg/dL) e colesterol (116-124 mg/dL). Em conclusão, a administração de Cnidoscolus chayamansa exerce efeitos hipoglicêmicos numa maneira dose dependente em comparação com Ruta graveolens e Citrus aurantium. As plantas avaliadas induzem mudanças nos níveis de lipídeos dependente da dose.


Several plants with hypoglycemic properties have been used in folk medicine and traditional healing systems around the world. The purpose of this work was to evaluate the effects of Ruta graveolens L., Rutaceae, Cnidoscolus chayamansa McVaugh, Euphorbiaceae, and Citrus aurantium L., Rutaceae, in a diabetic rat model to which the glucose levels were quantified every 24 hours by one month before of gastric administration of plants extract. Additionally, the cholesterol and triacylglycerides were evaluated using standard enzymatic techniques. The results showed that increases in the dose (0.5 to 1.5 g/kg) of Cnidoscolus chayamansa induce a high hypoglycemic effect (< 200 mg/dL). Another data indicate that Cnidoscolus chayamansa exerts variations in triacylglycerides (80-90 mg/dL) and cholesterol (88-96 mg/dL). Nevertheless, the administration of Citrus aurantium in the same doses was not sufficient for diminish the glucose levels (> 200 mg/dL). Other results, showed that Citrus aurantium exert changes in the concentration of triacylglycerides (158-172 mg/dL) and cholesterol (120-128 mg/dL). Finally, the administration of Ruta graveolens at dose of 0.5 mg/kg induces a hypoglycemic effect (< 200 mg/dL). Additionally, Ruta graveolens at dose of 0.5 to 1.5 g/kg induce variations in the triacylglycerides (110-120 mg/dL) and cholesterol (116-124 mg/dL) levels. In conclusion the administration of Cnidoscolus chayamansa it exerts hypoglycemic effects in a manner dose-dependent in comparison with both Ruta graveolens and Citrus aurantium. In addition, the plants evaluated induce changes in lipids levels dose-dependent.

15.
Steroids ; 73(5): 528-38, 2008 May.
Article in English | MEDLINE | ID: mdl-18314151

ABSTRACT

Several in vitro studies show that in animals and isolated cells, 17 beta-estradiol induces cardiovascular protective effects and it has also been observed that it reduces coronary heart disease risk. However, the use of estrogens to improve or protect cardiovascular function in humans has been controversial, this might be explained by the wide variety of effects, because estrogen receptors (ER) are expressed ubiquitously. Therefore, a cell-specific targeting therapeutic approach might be necessary. 17 beta-Estradiol was coupled to a large modified dextran through an aminocaproic spacer. For this study we used intact and gonadectomized male Wistar rats, 15 days after surgical procedure. Intravascular administration of 17 beta-estradiol-macromolecular conjugate, prior to coronary reperfusion diminishes the area of damage induced by coronary ischemia reperfusion (I/R) injury on an in vivo model. This effect was observed at 17 beta-estradiol sub-physiological concentrations [0.01 nmol/L], it is mediated by luminal endothelial ER alpha activation. 17 beta-Estradiol-macromolecular conjugate decreases phosphorylation level of PKC alpha and Akt, as part of the process to induce myocardial protection against coronary I/R. We proved that the hormone-macromolecular conjugate labeled with [3H]estradiol remained confined in the intravascular space the conjugate was not internalized into organs like heart, lung or liver. It is noteworthy that the 17 beta-estradiol-macromolecular conjugate has a slow renal elimination, which might increase its pharmacological advantage. We concluded that the stimulus of endothelial estrogen receptors is enough to decrease the myocardial damage induced by coronary reperfusion.


Subject(s)
Dextrans/therapeutic use , Estradiol/analogs & derivatives , Estradiol/therapeutic use , Estrogens/therapeutic use , Myocardial Reperfusion Injury/prevention & control , Animals , Estradiol/metabolism , Male , Myocardial Reperfusion Injury/metabolism , Myocardium/metabolism , Oncogene Protein v-akt/metabolism , Phosphorylation , Protein Kinase C-alpha/metabolism , Rats , Rats, Wistar
16.
Steroids ; 67(7): 611-9, 2002 Jun.
Article in English | MEDLINE | ID: mdl-11996934

ABSTRACT

The incidence of cardiovascular disease is greater in men than in premenopausal women. Testosterone has been considered a significant risk factor for cardiovascular disease, but testosterone's mechanism of action and its cellular site of action are still not clear. However, it is likely that non-genomic extracellular effects of the hormone are involved. With the aim of providing further information about this phenomenon, two membrane impermeant, macromolecular complexes of testosterone were synthesized and their cardiovascular effects were evaluated. We covalently bound testosterone (through carbon 3 or C-17 functional groups) to dextran (2 MDa) and evaluated its effects on isolated and perfused rat hearts (Langerdorff model). Our results showed that the macromolecular complexes increased vascular resistance similarly to free testosterone and blocked adenosine-induced vasodilatation. These effects were exerted rapidly and possibly through a non-genomic mechanism. Blockade of C-3 or C-17 functional groups by binding to macromolecular dextran induced no qualitative and/or quantitative changes in testosterone-induced effects.


Subject(s)
Dextrans/pharmacology , Testosterone/chemistry , Testosterone/pharmacology , Vasodilation/drug effects , Analysis of Variance , Animals , Cell Membrane Permeability , Dextrans/chemistry , In Vitro Techniques , Macromolecular Substances , Male , Rats , Vascular Resistance/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...